Auxilium Pharmaceuticals (AUXL), a specialty biotech that develops branded pharmaceuticals for urology and sexual health, in which New York-based Invus Public Equities filed SEC Form SC 13G/A on Tuesday indicating that it holds 2.6 million shares, a decrease from the 2.9 million shares it held at the end of Q4; and
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.